Celiac Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function?
You Are What You Eat-The Relationship between Diet, Microbiota, and Metabolic Disorders-A Review.
Celiac disease: a comprehensive current review.
Dermatitis Herpetiformis: Novel Perspectives.
Spectrum of gluten-related disorders: consensus on new nomenclature and classification.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2026.
- 1 industry development reported.
- Q3 2026A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
- Q1 2027A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free Diet
- Q2 2027A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)
- Q3 2027A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free Diet
Clinical MilestonesViewHide
- 2026-07-01A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten ExposureResults expected Q3 2026
- 2026-05-20A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)Results expected Q2 2027
- 2026-04-02A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free DietResults expected Q3 2027
- 2025-11-18A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free DietResults expected Q1 2027
- 2026-08-05A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free DietPrimary completion
- 2026-04-09Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in RemissionCompleted
- 2026-01-08A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free DietCompleted
Industry & MarketViewHide
- 2026-07-30Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to oneTrial news · Fierce Biotech
- 2026-08-05ClinicalA Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free DietPrimary completion
- 2026-07-30IndustryTakeda scraps another phase 2 celiac disease therapy, narrowing pipeline to oneTrial news · Fierce Biotech
- 2026-07-01ClinicalA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten ExposureResults expected Q3 2026
- 2026-05-20ClinicalA Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)Results expected Q2 2027
- 2026-04-09ClinicalDouble Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in RemissionCompleted
- 2026-04-02ClinicalA Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free DietResults expected Q3 2027
- 2026-01-08ClinicalA Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free DietCompleted
- 2025-11-18ClinicalA Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free DietResults expected Q1 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Capsule Endoscopy1
- Celiac Disease1
- Dermatitis Herpetiformis1
- Diet1
- Diet, Gluten-Free1
- Double-Balloon Enteroscopy1
- Dysbiosis1
- Energy Metabolism1
Leading journals6
- BMC medicine2
- Nutrients2
- Endoscopy1
- Frontiers in immunology1
- Journal of experimental botany1
- United European gastroenterology journal1
Leading researchers8
- Sanders DS3
- Volta U3
- Catassi C2
- Cellier C2
- Fasano A2
- Mulder CJ2
- Sapone A2
- Adler SN1
Affiliations (unnormalised)6
- University of Bologna2
- Beth Israel Deaconess Medical Center1
- Catholic University1
- Center for Celiac Research1
- Center for Celiac Research and Treatment1
- Centre Hospitalier Lyon Sud1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Celiac disease is a malabsorption syndrome triggered by ingestion of gluten-containing foods such as wheat, rye, and barley. It is characterized by inflammation of the small intestine, loss of microvilli structure, impaired intestinal absorption, and malnutrition.
The immediate trigger is exposure to gluten in the diet. The grounding also supports an autoimmune basis involving tissue transglutaminase as an autoantigen, with genetic susceptibility from HLA-DQ2/DQ8 and other genes contributing to disease development.
Gluten exposure leads to small-intestinal inflammation and damage to the mucosal surface, including loss of microvilli, which reduces absorptive capacity. The literature also supports an autoimmune mechanism and a contribution from gut microbiome dysbiosis to disease pathogenesis.
Ingestion of gluten-containing foods is the key exposure associated with disease expression. Genetic susceptibility, especially HLA-DQ2/DQ8 positivity, increases risk, and the literature also notes contributions from non-HLA genes and environmental factors such as viral infections and dysbiosis of the gut microbiota.
The primary treatment is a gluten-free diet. Guidelines also emphasize diagnosis and follow-up using serology and biopsy on a gluten-containing diet, with patient education and monitoring as part of management.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.